The verdict of the US district court in New Jersey is that Shilpa's generic infringes a US patent on multikinase inhibitor ...

Japanese drugmaker Eisai (TYO: 4523) said yesterday that it has received a favorable decision regarding the lawsuit filed in ...

A readily available sleep aid has been shown to have a surprising side effect on brain health, seemingly protecting the organ ...

Eisai shares fell sharply after its Alzheimer’s drug failed to secure marketing approval in the European Union. Shares were recently 12% lower at 5,852 yen, or about $38.06, Monday morning after ...

Patients with early Alzheimer’s disease treated with a medication developed by Eisai and Biogen for up to three years experienced less cognitive decline than what’s expected of untreated ...

today announced that the analysis of a combination study of E7386(*1), created through collaboration research with Eisai Co., ...

Shilpa Medicare failed to prove invalidity of patent covering Lenvima | Eisai says ruling keeps India-based generic maker’s ...

Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease. This authorisation makes the amyloid-beta (Aβ ...

The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If approved by the FDA, the LEQEMBI autoinjector could be used to administer ...

The fourth round of job cuts this year at global drugmaker Eisai‘s U.S. corporate headquarters will take effect on May 30. The oncology and neurology pharmaceutical company from Japan announced ...

European drug regulators rejected an Alzheimer’s therapy from Eisai Co. and Biogen Inc., a blow to the companies seeking to expand sales in one of the world’s biggest drug markets. The ...